Am J Transplant, Volume 19, Suppl 3 Archives - Page 86 of 214 - ATC Abstracts

2019 American Transplant Congress
Characterization of HLA Antibodies by C3d Assay and IgG Subclasses in Sensitized Kidney Transplant Patients
A. Casillas-Abundis, J. M. Arreola-Guerra, J. Alberu, M. I. Solis-G, L. Llorente, J. Granados, M. Vilatoba, R. Cruz-Martinez, L. Morales-Buenrostro, A. G. Contreras
Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico
*Purpose: To determine the detection rate of IgG subclasses (IgGsc) and C3d-binding HLA-antibodies (abs) in a cohort of highly sensitized kidney transplant patients.*Methods: We evaluated,…
2019 American Transplant Congress
Non-Invasive Monitoring of the Kidney Allograft
S. Bontha¹, G. Darville¹, C. Kuscu¹, C. Kuscu², A. Bajwa¹, J. Eason³, D. Maluf⁴, V. Mas⁵
¹Surgery, UTHSC, Memphis, TN, ²Surgery, UTHSC, memphis, TN, ³Surgery, Director of Transplant Institute - UTHSC, Memphis, TN, ⁴UTHSC, Memphis, TN, ⁵Surgery, Director of Transplant Research Institute, Memphis, TN
*Purpose: A major issue in kidney transplantation is the lack of validated non-invasive biomarkers for monitoring graft function, current biochemical markers (i.e., creatinine) have poor…
2019 American Transplant Congress
Validation of Gene Expression Signatures Associated with Antibody-Mediated Rejection (ABMR) in Renal Allograft Biopsies (Bx) of HLA-Sensitized Patients
H. Zhang¹, C. C. Nast², N. Ammerman³, A. A. Vo³, S. C. Jordan³, M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, ³Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: "Thoroughly validated gene transcripts” in renal Bx was adopted as one of the criteria for ABMR diagnosis in the latest Banff classification. Previously, we…
2019 American Transplant Congress
Predicting Kidney Discards with Donor Admission Text
A. Placona, C. Martinez, B. Carrico
United Network for Organ Sharing, Richmond, VA
*Purpose: Kidney discard rates have increased in part due to technological advancements and deceased donor policy updates that allow for recovery of organs at increased…
2019 American Transplant Congress
Effect of Human Leukocytic Antigen Matching on Clinical Outcomes after Deceased Donor Renal Allograft Transplant: A Single Centre Experience
M. E. Gramlick¹, M. K. Heer², S. Yausis², P. R. Trevillian²
¹Department of Surgery, John Hunter Hospital, Newcastle, Australia, ²Newcastle Transplant Unit, John Hunter Hospital, Newcastle, Australia
*Purpose: Human leucocyte antigen (HLA) matching has been the cornerstone of kidney allocation policies. With increasing expertise in assessing and managing immunological risks, the impact…
2019 American Transplant Congress
Long Term Outcomes in Kidney Transplant Recipients Receiving Everolimus (EVR) or Mycophenolate (MPS) in Combination with Tacrolimus (TAC)
K. Ficher, C. Rosso Felipe, Y. Cardoso Dreige, K. Linhares, A. Ferreira Brígido, S. Stopa, L. Viana, M. Cristelli, P. Gessolo Lins, W. Aguiar, H. Proença, R. Marco, M. Gerbase de Lima, H. Tedesco Silva Junior, J. Medina Pestana
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Detailed long-term data comparing the use of EVR or MPS in kidney transplant recipients receiving TAC is lacking.*Methods: This is a 5-years extension analysis…
2019 American Transplant Congress
Combination of Extended-Release Tacrolimus Plus Everolimus Once Daily in De Novo Kidney Transplant Recipients: ER-Tac vs LCPT
G. Spagnoletti, M. P. Salerno, F. De Gennaro, J. Romagnoli, F. Citterio
Surgery, Renal Transplant Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
*Purpose: Combination of Everolimus (EVR) with Tacrolimus (Tac) permits reduced calcineurin inhibitors exposure and, recently, has been demonstrated safe and effective. Two different once-daily Tacrolimus…
2019 American Transplant Congress
Risk Factors for Initial Sub- and Supra-Therapeutic Tacrolimus Trough Levels in Renal Transplant Recipients
M. Kapugi, K. Cunningham, C. D'Agostino, C. Kane, A. Novak, J. Schulte
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Sub-therapeutic tacrolimus trough levels have been associated with increased risk of rejection in renal transplant recipients and supra-therapeutic levels with infectious risks and drug…
2019 American Transplant Congress
Poor Long-Term Outcome of Liver Transplant Recipients with Preexisting Renal Insufficiency
M. Sterneck¹, M. Touma¹, T. Horvatits², S. Pischke², U. Herden³, A. Lohse², L. Fischer³
¹University Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²Department of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Department of Visceral Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: Due to the MELD based allocation system the number of patients undergoing orthotopic liver transplantation (OLT) with severely impaired renal function has markedly increased.…
2019 American Transplant Congress
Extreme Hyponatremia as a Risk Factor for Early Mortality after Liver Transplantation in the Model for End-Stage Liver Disease-Sodium Period
H. Mouzaihem, M. Safwan, L. C. Chau, D. Moonka, M. Abouljoud, S. Nagai
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: While we reported that implementation of MELD-Na based liver allocation improved waitlist outcomes in patients with hyponatremia, its impact on post-transplant outcomes in this…